Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Kmart settles hard-fought whistleblower case

Kmart Corp. agreed to pay $35.3 million to the federal government and a number of states to settle a whistleblower lawsuit.

Read More »

U.S. judge tosses verdict against AbbVie

A judge overturned a $150 million verdict against AbbVie, the first resulting from lawsuits claiming the company fraudulently misrepresented the risks of AndroGel.

Read More »

Ocular Therapeutix gets subpoena from SEC over eye pain drug

Ocular Therapeutix Inc. said the U.S. Securities and Exchange Commission (SEC) issued a subpoena seeking information about the company’s eye-pain drug Dextenza.

Read More »

Novartis drug Tasigna is approved by FDA as first CML therapy with Treatment-free Remission data in its label

Novartis announced that the FDA approved the inclusion of Treatment-free Remission data in the Tasigna (nilotinib) U. S. product label.

Read More »

Valeant says Bausch & Lomb’s over-the-counter eye drop gets FDA nod

Canadian drugmaker Valeant Pharmaceuticals International Inc. said the U.S. Food and Drug Administration approved Lumify drop to treat eye redness.

Read More »

Celgene’s Follicular Lymphoma Regimen Fails Phase III

Shares of Celgene plunged after the company announced Revlimid combined with Biogen’s Rituxan failed in a late-stage study of previously untreated patients with follicular lymphoma.

Read More »

FDA Rejects Agile’s Contraceptive Patch Twirla

Shares of Agile Therapeutics plunged more than 62 percent in early trading after the company announced that the U.S. FDA rejected its low-dose hormonal contraceptive patch called Twirla.

Read More »

U.S. FDA plans to let device makers report malfunctions less frequently

The U.S. Food and Drug Administration said it plans to let medical device makers report less serious malfunctions of some devices on a quarterly basis to cut down on repeated reviews of common problems.

Read More »

Combo therapy for melanoma gets priority review

The U.S. FDA granted priority review for Novartis’ Tafinlar in combination with Mekinist for treating some patients with advanced melanoma.

Read More »

Roche to buy U.S. cancer drugmaker Ignyta

Roche will buy U.S. cancer drugmaker Ignyta Inc. for $1.7 billion to broaden the Swiss drugmaker’s oncology portfolio globally.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2019 Focus: AI, AR/VR, Top 200 Medicines, Lions Health Takeaways, and more!


Ad Right Bottom